该研究通过观察性医疗结果合作伙伴关系 (OMOP) 和快速医疗保健互操作性资源 (FHIR) 的标准化，促进综合研究数据融入医疗保健系统和研究平台，从而提高了血液学中综合研究数据的实用性，特别是急性髓系白血病 (AML)格式。在我们之前的工作中，我们满足了对高质量患者数据的需求，并使用 CTAB-GAN 和标准化流程 (NFlow) 综合了四项多中心 AML 临床试验中 1606 名患者的数据。我们发布了生成的合成队列，准确地复制了关键人口统计、实验室、分子和细胞遗传学变量以及患者结果的分布，展示了高保真度和可用性。转换为 OMOP 格式，通过与相关 OMOP 数据集无缝结合，为比较观察性多中心研究开辟了途径，从而扩大了 AML 研究的范围。同样，FHIR 标准化有助于应用程序的进一步开发，例如通过 SMART-on-FHIR 平台，提供真实的测试数据。这项工作旨在营造一个更具协作性的研究环境，并促进 AML 护理和研究中创新工具和应用的开发。

This study advances the utility of synthetic study data in hematology, particularly for Acute Myeloid Leukemia (AML), by facilitating its integration into healthcare systems and research platforms through standardization into the Observational Medical Outcomes Partnership (OMOP) and Fast Healthcare Interoperability Resources (FHIR) formats. In our previous work, we addressed the need for high-quality patient data and used CTAB-GAN+ and Normalizing Flow (NFlow) to synthesize data from 1606 patients across four multicenter AML clinical trials. We published the generated synthetic cohorts, that accurately replicate the distributions of key demographic, laboratory, molecular, and cytogenetic variables, alongside patient outcomes, demonstrating high fidelity and usability. The conversion to the OMOP format opens avenues for comparative observational multi-center research by enabling seamless combination with related OMOP datasets, thereby broadening the scope of AML research. Similarly, standardization into FHIR facilitates further developments of applications, e.g. via the SMART-on-FHIR platform, offering realistic test data. This effort aims to foster a more collaborative research environment and facilitate the development of innovative tools and applications in AML care and research.